BPC-157 Dosing for Tendon Injuries: What the Research Actually Suggests

An important framing before the dosing discussion

There is no clinically validated BPC-157 dosing protocol for tendon injuries. There are no Phase 2 or Phase 3 trials establishing what dose, route, frequency, or duration produces meaningful clinical benefit for human tendinopathy. The FDA placed BPC-157 on Category 2 of the 503A bulk drug substances list in 2023 — reflecting the agency's determination that the safety package is insufficient for compounded human use.

What does exist: extensive rodent research from Predrag Sikiric's group and others, a few small early-phase human safety/PK reports, anecdotal user-community protocols that vary substantially, and athletic-recovery anecdotes that are hypothesis-generating but not evidence-grade. This article describes what those sources actually contain. It does not endorse any specific protocol or claim that any protocol is safe or effective for clinical use in your specific situation.

If you're considering BPC-157 for an injury, the appropriate first step is talking to a sports-medicine physician about evidence-based options (eccentric loading protocols, structured rehabilitation, PRP where appropriate). BPC-157 sits outside that evidence base.

What the preclinical dosing literature suggests

The rodent literature uses doses typically expressed as microgram-per-kilogram per day. Across the Sikiric group's tendon-injury models, ligament-injury models, and gut-protection models, doses commonly fall in the range of 10-40 mcg/kg/day administered intraperitoneally or subcutaneously. Some studies use single daily doses; others use twice-daily.

For a 70 kg human, allometric scaling (the conventional method for translating rodent doses to human-equivalent doses) gives approximately 0.5-2.5 mg per day. This wide range comes from variability in the rodent studies and from inherent uncertainty in cross-species dose translation. It's also worth noting that allometric scaling is a starting heuristic, not a validated translation method — actual safe and effective human doses can differ substantially from scaling predictions, in either direction.

The community-circulated protocols typically use doses substantially below the upper end of allometric translation — 250-500 mcg per day is the most common range, well below the 1-2 mg upper-end translation. Whether this represents appropriate caution, inadequate dosing, or simply where empirical experimentation has landed is unknowable without human trial data.

Routes of administration in community discussion

Four routes appear in community protocols:

Subcutaneous injection is the most common. Doses of 250-500 mcg per injection, once or twice daily, administered in subcutaneous tissue of the abdomen or near (but not directly into) the injured area. Proponents argue this maximizes systemic availability and avoids local tissue trauma.

Intramuscular injection near the injury site is sometimes discussed for tendinopathies, on the theory that local delivery concentrates the molecule at the site of action. The clinical justification for this is essentially community theory rather than published evidence.

Oral administration exists as a delivery format, with BPC-157 marketed in capsule form for gastric and intestinal indications. The molecule has plausible oral stability (the original isolation work was from gastric juice), but systemic bioavailability for tendon and ligament effects via oral dosing is questionable. Most community discussion of tendon-injury use favors subcutaneous over oral.

Topical formulations exist but have less community traction. Skin penetration of a 15-amino-acid peptide is limited; whether topical BPC-157 reaches deeper tissues at meaningful concentrations is unclear.

Common community dosing patterns

The most-discussed protocols share several common features. None of these represent medical advice; they describe what circulates in user communities.

Standard "recovery cycle": 250-500 mcg subcutaneous once or twice daily for 4-6 weeks. Often described as the baseline protocol for soft-tissue and tendon injuries. Some protocols extend to 8 weeks for chronic tendinopathies or significant injuries.

Higher-dose acute protocols: Some users report higher doses (750-1000 mcg per day) during the first 2-3 weeks of acute injury, then taper to maintenance. The acute-phase reasoning is theoretical — that early intervention with higher local concentration may produce better outcomes.

Twice-daily split dosing: Many protocols divide the daily dose into morning and evening administrations. The mechanistic argument is that BPC-157's plasma half-life is short (minutes), so multiple daily doses may maintain higher average tissue exposure.

Site-of-injury vs. systemic dosing: Some protocols specify injection "near the injury site"; others advocate for any subcutaneous location since systemic delivery should reach the target tissue regardless. The injection-near-the-injury rationale is not well-supported by pharmacokinetic data; the molecule distributes systemically after subcutaneous injection.

Combined protocols: Many community protocols pair BPC-157 with TB-500, IGF-1 LR3, GHK-Cu, or oral collagen peptides for connective-tissue support. See our Connective Tissue & Tendon Repair stack for the combination logic; combination-specific clinical evidence does not exist.

What injury type is most discussed

Some injury types dominate the community discussion more than others:

• Achilles tendinopathy — the most commonly discussed application, partly because Achilles tendinopathy is common in active populations and notoriously slow to heal with standard care alone
• Patellar tendinopathy ("jumper's knee") — second most-discussed, similar reasoning
• Rotator cuff strain and tendinopathy — significant discussion among lifters and overhead athletes
• Lateral and medial epicondylitis (tennis elbow, golfer's elbow) — substantial discussion in racquet sports and climbing communities
• Plantar fasciitis — frequently discussed; some practitioners argue plantar fascia is more analogous to ligament than tendon
• ACL and meniscus injuries post-surgery — discussed in rehabilitation contexts

The pattern across injury types is similar — most users report subjective improvement in return-to-training timelines compared to their prior healing experiences with similar injuries. Selection bias (people who didn't improve don't return to the forum to report it), natural history of soft-tissue healing (most tendinopathies improve over 3-6 months regardless of intervention), and placebo response (substantial in pain conditions) all argue for caution in interpreting these reports as evidence.

Reasonable framework if you're considering it

For users who decide to proceed despite the absence of clinical validation, several considerations are worth thinking through:

Talk to a knowledgeable clinician. A sports-medicine physician familiar with peptide use (many are not) can help interpret your specific injury, rule out contraindications, monitor for adverse events, and integrate any peptide use with evidence-based rehabilitation (which is where most of the clinical benefit comes from anyway).

Source quality matters substantially. Research-peptide market quality varies widely. Identity, purity, and endotoxin contamination are documented concerns. If you're going to use a research peptide, paying for third-party-tested product from a vendor with published certificates of analysis is meaningfully different from buying the cheapest option.

Don't skip rehabilitation. The single biggest factor in tendinopathy outcomes is the loading protocol — eccentric exercises, progressive resistance, and structured return-to-activity. Whatever pharmacologic intervention you add, the rehabilitation is doing most of the work. A protocol that combines BPC-157 with aggressive rehabilitation and a protocol that combines BPC-157 with nothing else are very different things.

Track functional outcomes, not just subjective sensations. Strength testing, range-of-motion measurements, and pain-during-activity scores are better outcome metrics than "it feels better." Subjective improvement in tendinopathy is highly susceptible to placebo response; functional metrics are harder to fool.

Set time-bound expectations. If you're going to try a 6-8 week protocol, decide upfront what "this is working" looks like and what "this isn't working" looks like. Without clear stopping criteria, users tend to extend indefinitely on insufficient evidence of benefit.

Be aware of contraindications. Active malignancy is the most commonly discussed contraindication — sustained pro-angiogenic signaling is theoretical concern with cancer biology. Pregnancy is uncharacterized for safety. Active autoimmune conditions warrant clinician input.

What we'd want to see (the gap in the field)

A reasonable next step for the BPC-157 field would be a Phase 2 RCT in a well-defined chronic tendinopathy population (Achilles or patellar tendinopathy), with primary endpoints on validated functional and pain measures plus imaging at 6 and 12 months. Such a trial would settle the dosing, efficacy, and safety questions that user-community experimentation cannot resolve.

The trial hasn't happened — and the reasons are revealing. No commercial sponsor has the incentive: BPC-157 isn't patentable in its current form, and the development costs aren't justified by the limited regulatory pathway. Academic interest exists but the funding for the kind of trial that would actually move the field is hard to assemble.

Until that gap closes, BPC-157 remains a research-grade peptide with strong preclinical signal and absent clinical validation. The community use will continue regardless; the appropriate posture is honest about what we know and don't know.